THERAPEUTIC USE OF FIBROBLASTS FOR USE IN WOUND HEALING

Information

  • Patent Application
  • 20230293595
  • Publication Number
    20230293595
  • Date Filed
    March 16, 2023
    2 years ago
  • Date Published
    September 21, 2023
    a year ago
Abstract
The present disclosure concerns use of activated or inactivated fibroblasts or fibroblast-derived materials, such as exosomes from fibroblasts, for wound care. The methods and compositions are useful for purpose of tissue differentiation, cell recruitment, differentiation of local stem cells, and expansion of local cells, such as keratocytes, vasal epithelial cells, myofibroblasts, and/or dermal fibroblasts, including for initiating and/or maintaining wound healing.
Description
Claims
  • 1. A method of treating one or more wounds in an individual, comprising the step of administering to the individual a therapeutically effective amount of a composition comprising fibroblasts and/or fibroblast-derived products.
  • 2. The method of claim 1, wherein said fibroblast-derived products comprises extracellular vesicles, exosomes, microvesicles, apoptotic bodies, and/or fragments or biologic components of fibroblast cells.
  • 3. The method of claim 1, further comprising administering to the individual a therapeutically effective amount of one or more of immune cells, keratinocytes, vasal epithelial cells and/or materials derived therefrom.
  • 4. The method of claim 1, wherein the fibroblast cells are myofibroblasts.
  • 5. (canceled)
  • 6. The method of claim 1, wherein the cells are activated, manipulated, and/or catalyzed.
  • 7. The method of claim 4, wherein the cells are activated, manipulated, and/or catalyzed upon exposure to mechanical means and/or using a biologic or genetic agent.
  • 8. The method of claim 7, wherein the mechanical means comprises light, laser, pressure, and/or stress.
  • 9. The method of claim 1, wherein the cells are activated upon exposure to cytokines, chemokines, growth factors, chemical agents, RNA, micro RNA, RNAi, DNA, viral nucleic acid, and/or exosomes.
  • 10. The method of claim 1, wherein the administering is into the wound, adjacent to the wound and/or on the surface of the wound.
  • 11. (canceled)
  • 12. The method of claim 1, further comprising administering one or more adjuvants to the individual.
  • 13. The method of claim 12, wherein the adjuvant is chemical, mechanical, viral, genetically modified components, or bacterial products-based.
  • 14. The method of claim 1, wherein the individual has diabetes, cancer, or is immunologically compromised.
  • 15. The method of claim 1, wherein the wound is chronic.
  • 16. The method of claim 1, wherein the wound is a cut, abrasion, bedsore, burn, or the individual has more than one of these.
  • 17-19. (canceled)
  • 20. The method of claim 1, wherein the individual is administered one or more antibiotics.
  • 21-22. (canceled)
  • 23. The method of claim 1, wherein following administration of the composition comprising fibroblasts and/or fibroblast-derived products to or at the wound, a cover is placed over at least part of the wound.
  • 24. The method of claim 23, wherein the cover acts as a barrier over at least part of the wound to prevent the fibroblasts and/or fibroblast-derived products to leave the wound.
  • 25-27. (canceled)
  • 28. A method of accelerating the healing of one or more wounds in an individual, comprising the step of administering to the individual a therapeutically effective amount of a composition comprising fibroblasts and/or fibroblast-derived products.
  • 29. The method of claim 28, wherein said fibroblast-derived products comprises extracellular vesicles, exosomes, microvesicles, apoptotic bodies, and/or fragments or biologic components of fibroblast cells.
Provisional Applications (3)
Number Date Country
63383498 Nov 2022 US
63379220 Oct 2022 US
63320388 Mar 2022 US